HER2-positive breast cancer is not considered hereditary. Unlike BRCA mutations, which pass from parent to child and raise breast cancer risk across generations, HER2 overexpression is almost always a change that happens inside tumor cells as cancer develops. It is not something you inherit from your parents, and having a HER2-positive diagnosis does not mean your children or siblings face a higher risk of the same subtype.
That said, the word “genetic” can mean different things, and the distinction matters. HER2-positive breast cancer is genetic in the sense that it involves a gene change, but it’s a change confined to the cancer cells themselves, not one woven into every cell in your body from birth.
Somatic vs. Inherited Gene Changes
Every cancer is driven by gene changes, but those changes fall into two very different categories. A germline (inherited) mutation is present in every cell of your body from conception. You got it from a parent, and you can pass it to your children. BRCA1 and BRCA2 mutations are the most well-known examples in breast cancer.
A somatic mutation, by contrast, develops later in life inside a specific group of cells. It isn’t inherited, and it can’t be passed on to your children. In HER2-positive breast cancer, the gene involved (called ERBB2) typically acquires extra copies inside tumor cells, a process known as gene amplification. About 80% of HER2 overexpression is caused by this amplification. The result is that cancer cells produce far too much HER2 protein on their surface, which fuels their growth. This amplification is a somatic event: it happens in the breast tissue, not in the DNA you were born with.
Moffitt Cancer Center states directly that HER2-positive breast cancers are not considered hereditary, even though having a family history of breast cancer in general can raise your overall risk.
How HER2 Status Relates to BRCA Mutations
Some people wonder whether carrying an inherited BRCA mutation makes HER2-positive cancer more likely. The opposite is actually true. HER2-positive breast cancers are rare among BRCA mutation carriers. Studies have found HER2 positivity in only about 2% to 10% of breast cancers in BRCA1 carriers, and roughly 7% to 13% in BRCA2 carriers. For comparison, about 15% to 20% of all breast cancers are HER2-positive. So carrying a BRCA mutation, if anything, makes a HER2-positive diagnosis less common, not more.
This means the two risk factors don’t usually overlap. Most people with HER2-positive breast cancer do not carry BRCA mutations, and most BRCA carriers who develop breast cancer end up with HER2-negative subtypes.
Why the Confusion Exists
Part of the confusion comes from the word “genetic” being used loosely. When your oncologist says your cancer is “HER2-positive,” they’re describing the tumor’s biology, something discovered by testing a biopsy sample, not your inherited DNA. Two different kinds of testing exist for exactly this reason.
Tumor genomic profiling looks at the DNA inside your cancer cells. It identifies changes that may be unique to the tumor (somatic) or, occasionally, present throughout your body (germline). Its main purpose is to guide treatment decisions, like whether HER2-targeted therapies will work. Germline genetic testing, on the other hand, sequences your inherited DNA, usually from a blood or saliva sample, to look for hereditary cancer syndromes like those caused by BRCA mutations. These are fundamentally different tests answering different questions.
When your pathology report says your tumor is HER2-positive, that result came from tumor testing. It tells you about the cancer, not about what you’ve inherited or what your family members might face.
How HER2 Status Is Determined
HER2 testing is done on a tissue sample from the tumor, typically using one or both of two methods. The first is immunohistochemistry (IHC), which measures how much HER2 protein sits on the surface of cancer cells. Results are scored from 0 to 3+. A score of 0 or 1+ means HER2-negative. A score of 3+ means HER2-positive.
A score of 2+ falls in an uncertain middle ground and triggers a second test called FISH (fluorescence in situ hybridization), which directly counts how many copies of the HER2 gene exist in the tumor cells. If FISH confirms amplification, the cancer is classified as HER2-positive. If not, it’s considered HER2-low, a newer category that has opened doors to additional treatment options using a class of drugs called antibody-drug conjugates.
There’s also a recently recognized category called HER2-ultralow, where IHC shows a score of 0 but with faint membrane staining visible in a small percentage of cells. Even these cancers may respond to certain antibody-drug conjugates, which is why precise scoring matters more than ever.
What This Means for Your Family
If you’ve been diagnosed with HER2-positive breast cancer, the HER2 overexpression itself is not something your relatives need to worry about inheriting. Your siblings, children, and parents do not carry an elevated risk of HER2-positive cancer specifically because of your diagnosis.
That said, breast cancer risk in general does have hereditary components. If breast cancer runs in your family, regardless of HER2 status, your relatives may benefit from earlier screening or germline genetic testing for mutations like BRCA1 and BRCA2. The key point is that any inherited risk would relate to breast cancer broadly, not to the HER2 subtype in particular.
There is one rare exception worth noting. Mutations in a gene called NF1, which sits close to the HER2 gene on chromosome 17, can be inherited and have been linked to increased HER2 expression in breast tumors. Both inherited and somatic NF1 mutations are associated with higher HER2 levels, possibly because deletions in NF1 can span into the neighboring HER2 gene region. NF1 mutations are uncommon in the general population, but they illustrate that the biology isn’t always perfectly clean-cut, even though the broad rule holds: HER2-positive breast cancer is not a hereditary condition.